Why do cancers occur where they do? A genetic and evolutionary approach.
Tumorigenesis is a form of somatic evolution, a topical subject given the advent of cancer genome sequencing. However, we contend that some features of Darwinian evolution have been neglected when cancer is studied, as have some a...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PHYLOCANCER
Phylogeography and somatic evolution of cancer tumor cells
2M€
Cerrado
EVOEPIC
Evolutionary mechanisms of epigenomic and chromosomal aberra...
1M€
Cerrado
PID2021-128976NB-I00
ESTIMACION PRECISA DE LOS PARAMETROS PARA LA INFERENCIA DE L...
254K€
Cerrado
INTRAHETEROSEQ
Molecular characterization of the role of intra tumor hetero...
1M€
Cerrado
MULTISELF
Multiple levels of selection in Fungi
206K€
Cerrado
PRE2019-090062
DESARROLLO DE NUEVOS METODOS DE GENETICA DE POBLACIONES PARA...
98K€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Tumorigenesis is a form of somatic evolution, a topical subject given the advent of cancer genome sequencing. However, we contend that some features of Darwinian evolution have been neglected when cancer is studied, as have some aspects of evolution that are special to cancers. For example, tumours comprise an expanding population of cells, cancers must occur within a normal human lifespan, and genotypes detrimental to growth of the tumour as a whole may be selected. These factors may render invalid the classical model in which successive mutations with large advantages arise and spread through the tumour in selective sweeps. To incorporate these neglected features and to test how tumorigenesis depends on factors such as mutation rate, selection and size constraints, we shall set up a comprehensive model of tumour growth incorporating cell birth, death, division and mutation parameters. We shall examine specific aspects of cancer-as-evolution in mice. By marking mutant clones using fluorescent proteins, we can track them and see how they persist, spread and die. We shall also determine the mutation profiles and genetic diversity of mutant clones and whole tumours in mice and humans using next-generation sequencing. Specific experiments will determine: (i) the fate of new advantageous clones arising in an existing tumour; (ii) whether new disadvantageous clones can persist in tumours; (iii) whether apparently maladaptive traits for tumour growth, such as suppressing the growth of competitors, can be selected; (iv) why do housekeeper gene mutations cause cancer in specific sites; (v) can cancer cells have too much genomic instability; and (vi) whether all cancers develop owing to driver mutations with big effects, or are there mini-drivers of tumorigenesis? There will be continual cross-talk between the experimental and modelling work. The results of the project will enhance our basic understanding of tumorigenesis and suggest strategies for anticancer therapy.